Peter Rieckmann

Summary

Country: Germany

Publications

  1. ncbi Escalating immunotherapy of multiple sclerosis--new aspects and practical application
    P Rieckmann
    Dept of Neurology, Josef Schneider Str 11, 97080, Wurzburg, Germany
    J Neurol 251:1329-39. 2004
  2. ncbi Neurodegeneration and clinical relevance for early treatment in multiple sclerosis
    Peter Rieckmann
    Department of Neurology, Julius Maximilians University of Wurzburg, Neurologische Universitätsklinik und Poliklinik, Josef Schneider Str 11, Wurzburg 97080, Germany
    Int MS J 12:42-51. 2005
  3. ncbi [Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations]
    M Maurer
    Klinische Forschungsgruppe für Multiple Sklerose und Neuroimmunologie, Neurologische Universitätsklinik Würzburg
    Nervenarzt 72:108-16. 2001
  4. ncbi Brain derived neurotrophic factor does not act on adult human cerebral endothelial cells
    Klemens Ruprecht
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians Universitat, 97080 Wurzburg, Germany
    Neurosci Lett 330:175-8. 2002
  5. ncbi Cytokine mRNA expression in patients with multiple sclerosis and fatigue
    Peter Flachenecker
    Department of Neurology, Julius Maximilians University of Wurzburg, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
    Mult Scler 10:165-9. 2004
  6. ncbi [Early multiple sclerosis therapy in the effects of public health economics]
    P Rieckmann
    Klinische Forschungsgruppe für Multiple Sklerose und Neuroimmunologie, Neurologische Universitätsklinik Würzburg
    Med Klin (Munich) 96:17-21. 2001
  7. ncbi Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis
    Peter Rieckmann
    Neurologische Universitätsklinik Würzburg, Wurzburg, Germany
    J Neurol 252:526-33. 2005
  8. ncbi Socio-economic aspects of neuroimmunological diseases
    Peter Rieckmann
    Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Dept of Neurology, University of Wuerzburg, Josef Schneider Str 11, 97080, Wurzburg, Germany
    J Neurol 253:V87-90. 2006
  9. ncbi Improving MS patient care
    Peter Rieckmann
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians University of Wurzburg, Josef Schneider Str 11, 97080, Wurzburg, Germany
    J Neurol 251:v69-v73. 2004
  10. ncbi Multiple sclerosis therapy: new strategies
    P Rieckmann
    Department of Neurology, University of Wurzburg, Josef Schneider Str 11, D 97080 Wurzburg, Germany
    Neurol Sci 26:S20. 2005

Collaborators

Detail Information

Publications80

  1. ncbi Escalating immunotherapy of multiple sclerosis--new aspects and practical application
    P Rieckmann
    Dept of Neurology, Josef Schneider Str 11, 97080, Wurzburg, Germany
    J Neurol 251:1329-39. 2004
    ..Moreover, in long-term treated patients, secondary treatment failure should be identified by pre-planned follow-up examinations, and other treatment options should then be considered...
  2. ncbi Neurodegeneration and clinical relevance for early treatment in multiple sclerosis
    Peter Rieckmann
    Department of Neurology, Julius Maximilians University of Wurzburg, Neurologische Universitätsklinik und Poliklinik, Josef Schneider Str 11, Wurzburg 97080, Germany
    Int MS J 12:42-51. 2005
    ..The urgent need to identify definitive markers of neuroprotection in humans remains. Such markers explain more about the underlying mechanisms of early MS pathophysiology...
  3. ncbi [Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations]
    M Maurer
    Klinische Forschungsgruppe für Multiple Sklerose und Neuroimmunologie, Neurologische Universitätsklinik Würzburg
    Nervenarzt 72:108-16. 2001
    ..These studies are often overinterpreted in relation to the therapy of MS. In this article, we critically evaluate the results of pharmacologic studies with respect to the dose-dependent efficacy of different interferon-beta preparations...
  4. ncbi Brain derived neurotrophic factor does not act on adult human cerebral endothelial cells
    Klemens Ruprecht
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians Universitat, 97080 Wurzburg, Germany
    Neurosci Lett 330:175-8. 2002
    ..These results demonstrate that adult HCEC are not a likely target for BDNF. Novel factors regulating HCEC remain to be identified...
  5. ncbi Cytokine mRNA expression in patients with multiple sclerosis and fatigue
    Peter Flachenecker
    Department of Neurology, Julius Maximilians University of Wurzburg, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
    Mult Scler 10:165-9. 2004
    ..Fatigue is one of the most common disabling symptoms in patients with multiple sclerosis (MS), but the putative role of proinflammatory cytokines remains to be elucidated...
  6. ncbi [Early multiple sclerosis therapy in the effects of public health economics]
    P Rieckmann
    Klinische Forschungsgruppe für Multiple Sklerose und Neuroimmunologie, Neurologische Universitätsklinik Würzburg
    Med Klin (Munich) 96:17-21. 2001
    ..For years, the costs of multiple sclerosis and the critically evaluated cost-benefit analyses were based on estimated figures...
  7. ncbi Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis
    Peter Rieckmann
    Neurologische Universitätsklinik Würzburg, Wurzburg, Germany
    J Neurol 252:526-33. 2005
    ..It modulates cytokine and adhesion molecule expression but long term in vivo effects of IFNbeta-1b on the immune system are not known in multiple sclerosis...
  8. ncbi Socio-economic aspects of neuroimmunological diseases
    Peter Rieckmann
    Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Dept of Neurology, University of Wuerzburg, Josef Schneider Str 11, 97080, Wurzburg, Germany
    J Neurol 253:V87-90. 2006
    ..Treatment decision should primarily be guided by evidence from high quality clinical studies and-if available-from direct head-to-head trials and cost-effectiveness analysis...
  9. ncbi Improving MS patient care
    Peter Rieckmann
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians University of Wurzburg, Josef Schneider Str 11, 97080, Wurzburg, Germany
    J Neurol 251:v69-v73. 2004
    ..In addition to optimising therapy, it is imperative to develop effective and properly resourced care services for MS patients that will address their complex and lifelong requirements...
  10. ncbi Multiple sclerosis therapy: new strategies
    P Rieckmann
    Department of Neurology, University of Wurzburg, Josef Schneider Str 11, D 97080 Wurzburg, Germany
    Neurol Sci 26:S20. 2005
  11. ncbi Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis
    Peter Rieckmann
    Department of Neurology, Wurzburg, Germany
    Drug Saf 27:745-56. 2004
    ....
  12. ncbi Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration
    Mathias Buttmann
    Department of Neurology, Julius Maximilians University, Wurzburg, Germany
    J Neurochem 102:1001-8. 2007
    ..Our results obtained with human brain endothelial cells demonstrate how statins may partially prevent an inflammatory-mediated blood-brain barrier breakdown in humans...
  13. ncbi CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis
    Mathias Maurer
    Department of Neurology, University of Wurzburg, Bayerische Julius Maximilians Universität, Josef Schneider Strasse 11, Wurzburg, Germany
    J Neuroimmunol 131:213-5. 2002
    ..The results suggest that dysregulation of CTLA4-driven down-regulation of T-cell function due a genetic dimorphism in exon 1 may be involved in the pathogenesis of different MS disease subtypes...
  14. ncbi A PD-1 polymorphism is associated with disease progression in multiple sclerosis
    Antje Kroner
    Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Bayerische Julius Maximilians Universität, Wurzburg, Germany
    Ann Neurol 58:50-7. 2005
    ..In conclusion, our data suggest that PD-1 polymorphism is a genetic modifier of the progression of MS, possibly through inducing a partial defect in PD-1-mediated inhibition of T-cell activation...
  15. ncbi Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up study
    Boris A Kallmann
    Department of Neurology, University of Wurzburg, Josef Schneider Strasse 11, 97080 Wurzburg, Germany
    J Neurol 251:30-4. 2004
    ..Magnetic resonance imaging (MRI) techniques used in clinical trials suggest a correlation between ventricular enlargement and axonal pathology and clinical disability in MS...
  16. ncbi CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation
    Ralf A Linker
    Clinical Research Group for Multiple Sclerosis, Department of Neurology, Julius Maximilians Universitat Wurzburg, Wurzburg, Germany
    Nat Med 8:620-4. 2002
    ..7). Here we identify a factor that modulates, in an inflammatory environment, glial cell survival and is an outcome determinant of EAE...
  17. doi Analysis of the stathmin rs182455 single nucleotide promoter polymorphism in patients with multiple sclerosis
    Mathias Buttmann
    Neurologische Klinik, Julius Maximilians Universitat, Wurzburg, Germany
    J Neurogenet 22:181-6. 2008
    ..We conclude that despite potential importance of stathmin in the pathogenesis of MS, the rs182455 polymorphism does not influence MS susceptibility or clinical disease course...
  18. ncbi Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction
    Mathias Buttmann
    Department of Neurology, Julius Maximilians University, Josef Schneider Str 11, D 97080 Wurzburg, Germany
    J Neuroimmunol 168:175-82. 2005
    ..IFN-beta may therefore trigger inflammatory skin reactions through local chemokine induction followed by rapid immune cell extravasation...
  19. ncbi Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls
    Felix Gronen
    Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians Universitat Wurzburg, 97080 Wurzburg, Germany
    J Neuroimmunol 180:185-92. 2006
    ..These data do not support the hypothesis that EBV could play a role in MS by inducing quantitatively altered EBV-specific CTL responses. Other pathogenic mechanisms for EBV in MS remain to be elucidated...
  20. ncbi Health outcomes in multiple sclerosis
    Peter Flachenecker
    Department of Neurology and Clinical Research Group for Neuroimmunology, Julius Maximilians Universitat Wurzburg, Wurzburg, Germany
    Curr Opin Neurol 17:257-61. 2004
    ..Here, we review cost-of-illness and cost-utility studies in multiple sclerosis published during the past 2 years...
  21. pmc Excitability decreasing central motor plasticity is retained in multiple sclerosis patients
    Daniel Zeller
    Dept, of Neurology, University of Wurzburg, Josef Schneider Str 11, 97080, Wurzburg, Germany
    BMC Neurol 12:92. 2012
    ..Because cTBS also may trigger behavioral effects through local interference with neuronal circuits, this approach also permitted investigating the functional role of the primary motor cortex (M1) in force control in patients with MS...
  22. ncbi TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response
    Mathias Buttmann
    Department of Neurology, Julius Maximilians University, Josef Schneider Strasse 11, Wurzburg, Germany
    J Neuroimmunol 190:170-6. 2007
    ..However, neither sTRAIL nor chemokine levels allowed prediction of one- and two-year clinical treatment response in 30 RRMS patients, prospectively followed by blinded investigators...
  23. pmc Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)
    Dirk Vordermark
    Dept of Radiation Oncology, University of Wurzburg, Wurzburg, Germany
    BMC Cancer 6:247. 2006
    ....
  24. ncbi The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS
    Berit Rosche
    Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Marburg, Germany Department of Neurology, Heinrich Heine University, Duesseldorf, Germany
    J Neuroimmunol 156:171-7. 2004
    ..We did not find differences in the frequency of the polymorphisms or surface expression between MS patients and controls. Overall, our findings do not support a role of HVEB and PVR genes in the development of MS...
  25. ncbi Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells
    Mathias Buttmann
    Department of Neurology, Julius Maximilians University, Josef Schneider Strasse 11, DE 97080 Würzburg, Germany
    J Vasc Res 44:51-60. 2007
    ..Therefore, IFN-beta potently induces endothelial chemokine expression at the transcriptional level...
  26. ncbi Early intervention in multiple sclerosis : better outcomes for patients and society?
    Peter Flachenecker
    Department of Neurology and Clinical Research Group for Neuroimmunology, Julius Maximilians University, Wurzburg, Germany
    Drugs 63:1525-33. 2003
    ....
  27. ncbi Interferon-beta1b in multiple sclerosis
    Mathias Buttmann
    Julius Maximilians University, Department of Neurology, Josef Schneider Str 11, D 97080 Wurzburg, Germany
    Expert Rev Neurother 7:227-39. 2007
    ..Finally, we discuss how novel drugs, especially monoclonal antibodies and orally administered immunosuppressants, might soon challenge the position of this well-established agent on the multiple sclerosis therapeutics market...
  28. ncbi sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study
    Peter Flachenecker
    Department of Neurology, Julius Maximilians Universitat Wurzburg, Josef Schneider Str 11, 97080 Wurzburg, Germany
    J Neurol 249:1001-3. 2002
    ..Thus, while sICAM-1 may be useful to indicate short-term activity of MS in terms of relapses and MRI activity, this does not hold true for the long-term activity of MS outside acute exacerbations...
  29. ncbi Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis
    Mathias Buttmann
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians University, Josef Schneider Str 11, D 97080 Wurzburg, Germany
    J Neuroimmunol 156:195-203. 2004
    ..Systemic IP-10/CXCL10 release induced by IFN-beta may influence its therapeutic effect--either negatively or positively...
  30. doi Treating multiple sclerosis with monoclonal antibodies
    Mathias Buttmann
    Julius Maximilians University, Department of Neurology, Josef Schneider Str 11, 97080 Wurzburg, Germany
    Expert Rev Neurother 8:433-55. 2008
    ..We finally develop a scenario for how each of the four mAbs might evolve into the market of MS therapeutics within the coming years...
  31. ncbi [Practical advice for a safe, effective and well tolerated therapy of multiple sclerosis]
    Mathias Buttmann
    Neurologische Universitatsklinik, Julius Maximilians Universitat Wurzburg
    MMW Fortschr Med . 2006
    ..An electrocardiogram recording and transthoracic echocardiography should be performed twice a year throughout therapy. With all of these drugs, effective contraception must be used, in particular with mitoxantrone and azathioprine...
  32. ncbi Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes
    Annette Kolb-Mäurer
    Department of Dermatology, University of Wurzburg, 97080 Wurzburg, Germany
    FEMS Immunol Med Microbiol 35:255-62. 2003
    ..The release of both stimulating cytokines IL-12 and IL-18 upon infection with entire bacteria suggests that attenuated strains of L. monocytogenes may be a valuable tool for subunit vaccine delivery...
  33. ncbi [Juvenile cerebral ischaemia caused by designer drugs]
    R Giess
    Neurologische Klinik, Universitat Wurzburg
    Dtsch Med Wochenschr 123:1308-12. 1998
    ..There was also a history of regular abuse of various drugs over several years by this socially well integrated young man...
  34. ncbi Human cerebral endothelial cells are a potential source for bioactive BDNF
    A Bayas
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Wurzburg, Germany
    Cytokine 19:55-8. 2002
    ..In contrast, BDNF expression was reduced by TNF-alpha in human umbilical vein endothelial cells (HUVEC). We conclude that HCEC likely to contribute to neuronal survival under physiological and inflammatory conditions...
  35. ncbi Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1
    B A Kallmann
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, University of Wurzburg, Germany
    Brain 123:687-97. 2000
    ..Increasing soluble VCAM-1 release during active inflammation could be another mechanism by which IFN-beta treatment exerts protective effects in multiple sclerosis patients...
  36. ncbi Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis
    B A Kallmann
    Department of Neurology, Universitätsklinikum der Bayerischen Julius Maximilians Universität, 97080 Wurzburg, Germany
    Mult Scler 12:58-65. 2006
    ..Together with clinical findings and MR imaging, combined EP data may help to identify patients at high risk of long-term clinical deterioration and guide decisions as to immunomodulatory treatment...
  37. ncbi Plasma exchange for severe optic neuritis: treatment of 10 patients
    K Ruprecht
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Julius Maximilians University, Josef Schneider Str 11, 97080 Wurzburg, Germany
    Neurology 63:1081-3. 2004
    ..On follow-up, three of these patients continued to improve, two remained stable, and two had worsened again. PE may be beneficial as an escalating treatment in a subset of patients with severe ON. A controlled trial is warranted...
  38. doi Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations
    H Wiendl
    Department of Neurology and Clinical Research, Unit for MS and Neuroimmunology, University of Wurzburg, Wurzburg, Germany
    J Neurol 255:1449-63. 2008
    ..The review also outlines a few areas of controversy and delineates the need for future research...
  39. ncbi Painful vascular compression syndrome of the sciatic nerve caused by gluteal varicosities
    M Bendszus
    Department of Neuroradiology, University of Wurzburg, Germany
    Neurology 61:985-7. 2003
    ..Decompression of the nerve resulted in complete and permanent pain relief. Sciatic or buttock pain in patients with varicosities and pain provocation in the sitting or lying position suggests this neurovascular compression syndrome...
  40. ncbi Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters
    P Flachenecker
    Department of Neurology, Julius Maximilians Universitat Wurzburg, Wurzburg, Germany
    Mult Scler 8:523-6. 2002
    ..Secondly, to further clarify the nature of fatigue, we investigated its relation to physical disability, course of the disease, immunotherapy, and depression...
  41. ncbi Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells
    Wen Yu Chuang
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan Electronic address
    J Autoimmun 52:122-9. 2014
    ..In addition, our data support a 60-year-threshold for onset of 'true LOMG' and an LOMG/early-onset MG overlapping group of patients between 40 and 60. ..
  42. ncbi Selective loss of regulatory T cells in thymomas
    Philipp Strobel
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany
    Ann Neurol 56:901-4. 2004
    ..We conclude that imbalance between effector and regulatory T cells in thymomas may be involved in modulation of onset and/or severity of MG...
  43. ncbi Influence of VEGF-R2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC)
    Sven Wagner
    Department of Neurosurgery, University of Wuerzburg, Germany
    J Neurooncol 62:221-31. 2003
    ....
  44. pmc Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown
    Axel Haarmann
    Department of Neurology, Julius Maximilian University, Wurzburg, Germany
    PLoS ONE 5:e13568. 2010
    ..Here we studied the regulation of JAM-A expression in cultured brain EC and evaluated sJAM-A as a serum biomarker of blood-brain barrier (BBB) function...
  45. ncbi Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis
    Peter Rieckmann
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians University, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
    Curr Opin Neurol 15:361-70. 2002
    ..Factors that are involved in functional impairment of axonal conduction and those elements that are responsible for direct structural damage to the axon are both potential targets for therapeutic interventions...
  46. ncbi Association of a null mutation in the CNTF gene with early onset of multiple sclerosis
    Ralf Giess
    Department of Neurology, University of Wurzburg, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
    Arch Neurol 59:407-9. 2002
    ..Ciliary neurotrophic factor (CNTF) is a potent survival factor for neurons and oligodendrocytes and may be relevant in reducing tissue destruction during inflammatory attacks...
  47. doi Functional role of ipsilateral motor areas in multiple sclerosis
    Daniel Zeller
    Department of Neurology, University of Wurzburg, Wurzburg, Germany
    J Neurol Neurosurg Psychiatry 82:578-83. 2011
    ..The authors examined the role of two ipsilateral motor areas during performance of a simple motor task in MS patients in relation to their motor impairment and CNS injury...
  48. ncbi Effects of oncostatin M on human cerebral endothelial cells and expression in inflammatory brain lesions
    K Ruprecht
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians University, Wurzburg, Germany
    J Neuropathol Exp Neurol 60:1087-98. 2001
    ..immunoreactivity was absent from the parenchyma. These data suggest that immunoregulatory functions in human cerebral endothelial cells may be a mechanism by which OSM participates in the pathophysiology of inflammatory brain disease...
  49. ncbi Impact of the Asp299Gly polymorphism in the toll-like receptor 4 (tlr-4) gene on disease course of multiple sclerosis
    A Kroner
    Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Bayerische Julius Maximilians Universität Würzburg, Josef Schneider Str 11, 97080 Wurzburg, Germany
    J Neuroimmunol 165:161-5. 2005
    ..01). However, these functional changes seem not to have any impact on the clinical presentation of MS patients with different TLR-4 genotypes...
  50. ncbi Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosis
    Klemens Ruprecht
    Department of Neurology, Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Wurzburg, Germany
    J Neurovirol 12:65-71. 2006
    ....
  51. ncbi The blood-brain barrier as target of multiple sclerosis research and therapy. Report of an international scientific meeting, Würzburg, January 23/24, 2004
    Ralf Gold
    Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Wurzburg, Germany
    J Neuroimmunol 152:1-4. 2004
  52. ncbi Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse
    Georg Becker
    Department of Neurology, Bayerische Julius Maximilians Universität Würzburg, Germany
    Mov Disord 17:710-6. 2002
    ..This suggests a link between both disorders. A peripheral trauma to the nerve roots may precipitate dystonic movements in susceptible patients and chronic dystonic muscle contraction would account for the persistent nuchal pain...
  53. pmc Future MS care: a consensus statement of the MS in the 21st Century Steering Group
    Peter Rieckmann
    Department of Neurology, Sozialstiftung Bamberg Hospital, Bamberg, Germany
    J Neurol 260:462-9. 2013
    ....
  54. ncbi Characteristic gene expression profile of primary human cerebral endothelial cells
    Boris A Kallmann
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Dept of Neurology, Julius Maximilians University of Wurzburg, Germany
    FASEB J 16:589-91. 2002
    ..Identification and further functional characterization of genes specifically expressed by cerebral endothelial cells will have important impact on our understanding of endothelial function at the BBB...
  55. ncbi A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation
    Mathias Maurer
    Department of Neurology, Bayerische Julius Maximilians Universität, Josef Schneider Strasse 11, 97080 Wurzburg, Germany
    Immunogenetics 54:1-8. 2002
    ..Our results suggest that the G allele at position +49 of exon 1 affects the CTLA4-driven down-regulation of T-cell activation and may be an important factor in the pathogenesis of autoimmune diseases...
  56. doi Rapid-onset central motor plasticity in multiple sclerosis
    D Zeller
    Department of Neurology, University of Leipzig, Liebigstr 20, 04103 Leipzig, Germany
    Neurology 74:728-35. 2010
    ..To study rapid-onset central motor plasticity, and its relationship to motor impairment and CNS injury in patients with multiple sclerosis (MS)...
  57. ncbi Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis
    K G Kahl
    Department of Neurology, Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Julius Maximilians University, Wurzburg, Germany
    Psychoneuroendocrinology 27:671-81. 2002
    ..The possible contribution of Th1-type cytokines to the development of depression in MS is discussed...
  58. ncbi Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosis
    A Kroner
    Bayerische Julius Maximilians Universität, Department of Neurology, Wurzburg, Germany
    Tissue Antigens 64:70-3. 2004
    ..Thus, our data could not reveal any association between the MCP-1 -2518 polymorphism and susceptibility to or clinical disease course of MS...
  59. ncbi Modulation of cytokine mRNA expression by brain-derived neurotrophic factor and nerve growth factor in human immune cells
    A Bayas
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Wurzburg, Josef Schneider Strasse 11, 97080 Wurzburg, Germany
    Neurosci Lett 335:155-8. 2003
    ..No major effects were detected at the cytokine protein level. In conclusion, our results suggest a partial effect of neurotrophins on immune cells, which may be modified by other signals...
  60. ncbi Analysis of the C/T(-1) single nucleotide polymorphism in the CD40 gene in multiple sclerosis
    D Buck
    Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Bayerische Julius Maximilians Universität, Wurzburg, Germany
    Tissue Antigens 68:335-8. 2006
    ....
  61. ncbi Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules
    V Hummel
    Department of Neurology, , , Germany
    J Neuropathol Exp Neurol 60:320-7. 2001
    ..These data suggest that MMPs produced by HCEC are actively involved in the shedding of soluble adhesion molecules at the BBB...
  62. ncbi Serum levels of macrophage-derived protein MRP-8/14 are elevated in active multiple sclerosis
    T Bogumil
    Department of Neurology, University of Gottingen, Germany
    Neurosci Lett 247:195-7. 1998
    ..These results may indicate an early activation of macrophages in the formation of demyelinating MS plaques. In addition, increased serum levels of MRP-8/14 may prove to be a useful paraclinical disease activity parameter in MS patients...
  63. ncbi A longitudinal prospective study of soluble adhesion molecules in acute stroke
    A Bitsch
    Department of Neurology, Georg August University, Gottingen, Germany
    Stroke 29:2129-35. 1998
    ..Methods-Plasma levels of soluble (s) ICAM-1, sVCAM-1, and sE-selectin were repeatedly determined by ELISA in 38 patients during a period of 14 days after acute cerebral ischemia...
  64. ncbi Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis
    K G Kahl
    Department of Neurology, Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Julius Maximilians University, Wurzburg, Germany
    J Neurol Sci 200:53-5. 2002
    ....
  65. pmc Triggering receptor expressed on myeloid cells-1 (TREM-1) expression on gastric epithelium: implication for a role of TREM-1 in Helicobacter pylori infection
    B Schmausser
    Institut für Pathologie der Universität Würzburg, Wurzburg, Germany
    Clin Exp Immunol 152:88-94. 2008
    ..This is the first study localizing TREM-1 on gastric epithelium. Functional data suggest that TREM-1 expressed on gastric epithelium amplifies inflammation of the underlying gastric mucosa by up-regulation of IL-8...
  66. ncbi Influenza vaccination in MS: absence of T-cell response against white matter proteins
    N F Moriabadi
    Clinical Research Unit for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Julius Maximilians Universitat, Wurzburg, Germany
    Neurology 56:938-43. 2001
    ..Natural infections bear the risk of triggering MS bouts, whereas epidemiologic studies have not delineated an increased risk for disease activity after influenza virus vaccination...
  67. ncbi Cytokine mRNA expression patterns in the disease course of female adolescents with anorexia nervosa
    Kai G Kahl
    Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
    Psychoneuroendocrinology 29:13-20. 2004
    ..7 +/- 0.5) while IL-6 mRNA expression decreased. We interpret our results as suggesting that TNF-alpha may contribute to metabolic abnormalities in anorexia nervosa even after goal BMI is achieved...
  68. ncbi Lack of immune responses against multiple sclerosis-associated retrovirus/human endogenous retrovirus W in patients with multiple sclerosis
    Klemens Ruprecht
    Institute for Virology, Saarland University Hospital, Homburg Saar, Germany
    J Neurovirol 14:143-51. 2008
    ..While this may be due to immunological tolerance of physiologically expressed HERV-W proteins, strategies other than measurement of immune responses will be required to further elucidate the relationship between MSRV/HERV-W and MS...
  69. ncbi [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)]
    Peter Rieckmann
    Nervenarzt 77:1506-18. 2006
    ..Recommendations for optimized care of MS patients are also new, thus implementing a resolution of the European Parliament...
  70. ncbi Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades
    Sabine Miebach
    Department of Neurosurgery, Klinikum Grosshadern, Ludwig Maximilians University Munich, Munich, Germany
    J Neurooncol 76:39-48. 2006
    ..In first phenotypical and functional analyses, NBEC, LGEC and HGEC show remarkable differences. EC from all tumors could be grown in culture. However, passage related changes of EC phenotype demand very early passages to work with...
  71. ncbi Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis
    Susanne Vogler
    Department of Immunology, University of Rostock, Germany
    J Mol Med (Berl) 83:806-11. 2005
    ..Thus, UCP2 promoter polymorphism may contribute to MS susceptibility by regulating the level of UCP2 protein in the central nervous and/or the immune systems...
  72. pmc mtDNA nt13708A variant increases the risk of multiple sclerosis
    Xinhua Yu
    Section of Immunogenetics, University of Rostock, Rostock, Germany
    PLoS ONE 3:e1530. 2008
    ..Mitochondrial DNA (mtDNA) polymorphism is a possible factor contributing to the maternal parent-of-origin effect in multiple sclerosis (MS) susceptibility...
  73. ncbi Building up the blood-brain barrier
    Peter Rieckmann
    Nat Med 9:828-9. 2003
  74. ncbi Inflammation in multiple sclerosis: the good, the bad, and the complex
    Gianvito Martino
    Department of Neuroscience, San Raffaele Scientific Institute, Milan, Italy
    Lancet Neurol 1:499-509. 2002
    ..Precise identification of the inflammatory pathways to be targeted in the different phases of the disease and the timing of such interventions are therefore crucial...
  75. ncbi Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions
    Hervé Perron
    bioMerieux, R and D, Chemin de l orme, 69280 Marcy l Etoile, France
    J Neurovirol 11:23-33. 2005
    ..This is compatible with a pathophysiological role in MS, but also illustrates the ambivalence of such HERV antigens, which can be expressed in cell-specific patterns, under physiological or pathological conditions...
  76. ncbi Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patients
    Reiner Füth
    German Diabetes Centre, German Diabetes Research Institute at the Heinrich Heine University Düsseldorf, Auf m Hennekamp 65, 40225 Dusseldorf, Germany
    Cytokine 27:166-72. 2004
    ..This study shows that gene expression patterns of circulating leukocytes may present an important new diagnostic tool to predict clinical outcome in patients with inflammatory vascular diseases...
  77. pmc Downregulation of CXCR1 and CXCR2 expression on human neutrophils by Helicobacter pylori: a new pathomechanism in H. pylori infection?
    Bernd Schmausser
    Institut fur Pathologie, Universitat Wurzburg, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Infect Immun 72:6773-9. 2004
    ..pylori infection. Downregulation of CXCR1 and CXCR2 expression on neutrophils in H. pylori infection by H. pylori itself may represent a new mechanism of modulating neutrophil migration and activation in the gastric mucosa...
  78. pmc UM 9(5)h and UM 9(5)p, human and porcine noncoding transcripts with preferential expression in the cerebellum
    Uwe Michel
    Neurologische Klinik, 37075 Gottingen, Germany
    RNA 8:1538-47. 2002
    ..They are part of larger transcripts, which are transcribed from single-copy genes, they have very similar tissue distributions, and their sequences are colinear with the respective genomic fragment...
  79. ncbi Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms
    Philipp Strobel
    Institute of Pathology, University Hospital Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68135 Mannheim, Germany
    Ann N Y Acad Sci 1132:143-56. 2008
    ..The findings imply that IFN-gamma and STAT-1 signaling play a role in MHCII expression in the human thymus and in the pathogenesis of paraneoplastic MG...